LabGenius’ Post

In business news, LabGenius, a drug discovery company pioneering the use of machine learning for the discovery of novel therapeutic antibodies, announced that it has closed a £35 million Series B financing round. The investment brings LabGenius’ total funding to date to £58 million. LabGenius will use the capital raised to expand the scope of its ML-driven discovery platform and progress a wholly-owned pipeline of multispecific antibodies towards the clinic. Building on the success of a recent research collaboration with Sanofi, the extended platform capability will facilitate broader strategic partnerships across multiple therapeutic modalities.  https://lnkd.in/erQrPsTE